Date | Price Target | Rating | Analyst |
---|---|---|---|
9/3/2024 | $263.00 | Outperform | Leerink Partners |
7/31/2024 | $289.00 → $150.00 | Overweight → Equal Weight | Wells Fargo |
7/31/2024 | $165.00 → $178.00 | Buy → Neutral | Citigroup |
2/23/2024 | $284.00 → $250.00 | Overweight → Neutral | JP Morgan |
9/6/2023 | $265.00 | Equal-Weight | Morgan Stanley |
7/19/2023 | $375.00 | Outperform | Robert W. Baird |
3/29/2023 | Buy → Hold | Needham | |
1/30/2023 | $275.00 | Overweight | Piper Sandler |
8-K - Penumbra Inc (0001321732) (Filer)
10-Q - Penumbra Inc (0001321732) (Filer)
8-K - Penumbra Inc (0001321732) (Filer)
Leerink Partners initiated coverage of Penumbra with a rating of Outperform and set a new price target of $263.00
Wells Fargo downgraded Penumbra from Overweight to Equal Weight and set a new price target of $150.00 from $289.00 previously
Citigroup downgraded Penumbra from Buy to Neutral and set a new price target of $178.00 from $165.00 previously
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma
SC 13G - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
Truist Securities analyst Richard Newitter maintains Penumbra (NYSE:PEN) with a Buy and lowers the price target from $280 to $230.
Morgan Stanley analyst Kallum Titchmarsh maintains Penumbra (NYSE:PEN) with a Equal-Weight and lowers the price target from $235 to $210.
In the last three months, 4 analysts have published ratings on Penumbra (NYSE:PEN), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $257.25, along with a high estimate of $272.00 and a low estimate of $232.00. This current
ALAMEDA, Calif., July 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024. Revenue of $299.4 million in the second quarter of 2024, an increase of 14.5% or 14.7% in constant currency1, compared to the second quarter of 2023.U.S. thrombectomy revenue of $153.7 million in the second quarter of 2024 increased 24.9% compared to the second quarter of 2023.Loss from operations of $81.0 million, which includes $110.3 million of one-time non-cash imp
ALAMEDA, Calif., July 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2024 after market close on Tuesday, July 30, 2024 at 4:30 PM Eastern Time. A press release with second quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "
ALAMEDA, Calif., May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. Revenue of $278.7 million in the first quarter of 2024, an increase of 15.4% or 15.2% in constant currency1, compared to the first quarter of 2023.U.S. thrombectomy revenue of $150.3 million in the first quarter of 2024 increased 35.2% compared to the first quarter of 2023.Non-GAAP income from operations1 of $19.3 million in the first quarter of 2024.Adjusted EBITDA1 of
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quicklyLightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombusLightning Bolt™ 7 is designed to enhance the ability to rapidly remove blood clots in the arteries with modulated aspiration, addressing conditions such as acute limb ischemia (ALI), hibernating thrombus and visceral occlusionsALAMEDA, Calif., Sept. 16, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced it has secured CE Mark i
ALAMEDA, Calif., Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024. Event: Baird Global Healthcare ConferenceDate: Tuesday, September 10, 2024Time: 9:05am ET/6:05am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the e
ALAMEDA, Calif., Aug. 21, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. Event: Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 2:15pm ET/11:15am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event. About
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)